© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
September 10, 2008
Diabetes and inflammation influence the development of atherosclerosis. We performed a study that showed the inflammatory markers high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 were lowered with the use of fenofibrate, simvastatin, and combination therapy. The anti-inflammatory effects were most pronounced among patients with elevated baseline inflammatory markers. Combination therapy significantly altered lipid concentrations and exerted a greater positive effect on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides than monotherapy with either drug.
Atopic Dermatitis Severity Linked to Incremental Societal Healthcare Costs
Strong Response Maintenance for Plaque Psoriasis Patients Using Tildrakizumab
Clinical Efficacy, Safety of Brolucizumab Similar to Trial Results for nAMD Patients